Our Autologous Approach
Our lead autologous product, TAC-HER2, is designed to target HER2-expressing tumors. We will pursue various other novel targets with an autologous approach.
Our lead autologous product, TAC-HER2, is designed to target HER2-expressing tumors. We will pursue various other novel targets with an autologous approach.
Given the current challenges of existing autologous therapies, we have entered a risk-sharing collaboration with Lonza to use their Cocoon™ Manufacturing System. It effectively bypasses many of the industry-standard manual steps in product production by streamlining sample processing.